Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Zero based budgeting for newbies guides you to assign every dollar a purpose, ensuring zero leftover funds and sharper goal alignment.
15,575 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Navitas Semiconductor is pursuing an AI data-center power strategy built around 800V architecture. This move could re...
GE Vernova sparked intraday excitement as investors reacted to new outlooks on its energy portfolio. This piece break...
Oxford Square Capital trades at a 24% yield, yet a steep NAV decline and Q4 losses cast doubt on earnings durability....
Icahn Enterprises just added a sizable stake in Centuri Holdings, signaling a continued conviction in North America's...
Paysign's 2025 earnings paint a picture of a niche fintech player balancing steady card-services revenue with new par...
Are you leaning toward megacap growth or small-cap opportunities? This guide breaks down MGK vs IWM, reveals how to b...
AppLovin exposes investors to a volatile mix of ad spend cycles and AI disruption fears. This guide breaks down the d...
Have tech stocks finally run out of road? This data-driven exploration breaks down valuations, growth drivers, and ho...
A Crinetics director sells 5,000 shares as the stock dips. This guide breaks down what insider moves really mean for ...
Williams Companies positions its gas and power assets to benefit from the rapid expansion of AI data centers, signali...
A notable stake in TowneBank marks a strategic bet by Patriot Financial Partners. This article breaks down what the i...